Drug Profile
Elsubrutinib/ upadacitinib - AbbVie
Alternative Names: ABBV 105/ABT 494 -AbbVie; ABBV-105/upadacitinib-combination; ABBV-599Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AbbVie Germany
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Fluorocarbons; Imidazoles; Pyrazines; Pyrroles; Pyrrolidines; Skin disorder therapies; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Janus kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 03 Jun 2023 Efficacy data from a phase II trial in Systemic lupus erythematosus presented at the 24th Annual Congress of the European League Against Rheumatism (EULAR-2023)
- 31 May 2023 Efficacy and adverse events data from a phase II trial in Systemic lupus erythematosus presented at the 24th Annual Congress of the European League Against Rheumatism (EULAR-2023)
- 31 May 2023 Pharmacokinetics, efficacy and adverse events data from a phase II trial in Rheumatoid arthritis presented at the 24th Annual Congress of the European League Against Rheumatism (EULAR-2023)